Holzer Holzer & Fistel, LLC Announces Investigation into the Proposed Buyout
of PROLOR Biotech, Inc.
ATLANTA -- April 24, 2013
Holzer Holzer & Fistel, LLC is investigating whether the directors of PROLOR
Biotech, Inc. (“PROLOR” or the “Company”) (NASDAQ: PBTH) complied with their
fiduciary duties in approving the proposed acquisition of the Company by OPKO
Health Inc. According to the Company’s announcement, if the deal closes PROLOR
shareholders will receive 0.9951 shares of OPKO stock for each share of PBTH
owned, which values the PROLOR stock at $7 per share. The firm’s investigation
seeks to determine, among other things, whether the consideration to be paid
to PROLOR shareholders is fair and adequate.
Current holders of PROLOR common stock with questions concerning their legal
rights are encouraged to contact Holzer Holzer & Fistel, LLC and its attorneys
Michael I. Fistel, Jr., Esq. or Marshall P. Dees, Esq. via email at
firstname.lastname@example.org, or email@example.com, or via toll-free telephone at
Holzer Holzer & Fistel, LLC dedicates its practice to vigorous representation
of shareholders and investors in litigation nationwide, including shareholder
class action and derivative litigation. More information about the firm is
available through its website, www.holzerlaw.com and upon request from the
firm. Holzer Holzer & Fistel, LLC has paid for the dissemination of this
promotional communication, and Michael I. Fistel, Jr. is the attorney
responsible for its content.
Holzer Holzer & Fistel, LLC
Michael I. Fistel, Jr., Esq.
Marshall P. Dees, Esq.
Press spacebar to pause and continue. Press esc to stop.